5. Effectiveness of Breast Cancer Screening

Total Page:16

File Type:pdf, Size:1020Kb

5. Effectiveness of Breast Cancer Screening 5. EFFECTIVENESS OF BREAST CANCER SCREENING This section considers measures of screening Nevertheless, the performance of a screening quality and major beneficial and harmful programme should be monitored to identify and outcomes. Beneficial outcomes include reduc- remedy shortcomings before enough time has tions in deaths from breast cancer and in elapsed to enable observation of mortality effects. advanced-stage disease, and the main example of a harmful outcome is overdiagnosis of breast (a) Screening standards cancer. The absolute reduction in breast cancer The randomized trials performed during mortality achieved by a particular screening the past 30 years have enabled the suggestion programme is the most crucial indicator of of several indicators of quality assurance for a programme’s effectiveness. This may vary screening services (Day et al., 1989; Tabár et according to the risk of breast cancer death in al., 1992; Feig, 2007; Perry et al., 2008; Wilson the target population, the rate of participation & Liston, 2011), including screening participa- in screening programmes, and the time scale tion rates, rates of recall for assessment, rates observed (Duffy et al., 2013). The technical quality of percutaneous and surgical biopsy, and breast of the screening, in both radiographic and radio- cancer detection rates. Detection rates are often logical terms, also has an impact on breast cancer classified by invasive/in situ status, tumour size, mortality. The observational analysis of breast lymph-node status, and histological grade. cancer mortality and of a screening programme’s Table 5.1 and Table 5.2 show selected quality performance may be assessed against several standards developed in England by the National process indicators. The major indicators of both Health Service (NHS) (Wilson & Liston, 2011; the screening process and the clinical outcome, Department of Health, 2013) and in the USA and the associated analytical methodologies, are by the Agency for Health Care Policy and described below. Research and endorsed by the American College of Radiology, respectively (Bassett et al., 1994; 5.1 Indicators for monitoring and D’Orsi et al., 2013). Similar sets of standards exist for screening in Australia, Canada, and Europe evaluating effectiveness (National Quality Management Committee of 5.1.1 Performance indicators BreastScreen Australia, 2008; Perry et al., 2008; CPAC, 2013) (see Section 3.2). The programmes As a general principle, the most important specify standards – related mainly to the indicator of the effectiveness of a screening screening process and not directly to technical programme is its effect on breast cancer mortality. 281 IARC HANDBOOKS OF CANCER PREVENTION – 15 Table 5.1 Minimum quality standards and targets considered in the National Health Service breast screening programme in England Criterion Standard Target Attendance at screening ≥ 70% 80% Invasive cancers detected, prevalent screen ≥ 3.6/1000 ≥ 5.1/1000 Invasive cancers detected, incident screen ≥ 4.1/1000 ≥ 5.7/1000 In situ cancers detected, prevalent screen ≥ 0.5/1000 None specified In situ cancers detected, incident screen ≥ 0.6/1000 None specified Standardized detection ratio ≥ 1.0 ≥ 1.4 Invasive cancers < 15 mm, prevalent screen ≥ 2.0/1000 ≥ 2.8/1000 Invasive cancers < 15 mm, incident screen ≥ 2.3/1000 ≥ 3.1/1000 Mean glandular radiation dose for standard breast ≤ 2.5 mGy None specified Number of repeat examinations (% of total examinations) < 3% < 2% Recall for assessment (% of prevalent screens) < 10% < 7% Recall for assessment (% of incident screens) < 7% < 5% Short-term recall (% of screened women) < 0.25% ≤ 0.12% Non-operative diagnosis (% of cancers) ≥ 90% ≥ 95% Non-operative diagnosis (% of DCIS) ≥ 85% ≥ 90% Benign biopsies (prevalent screens) < 1.5/1000 < 1.0/1000 Benign biopsies (incident screens) < 1.0/1000 < 0.75/1000 Interval cancers within 24 months (screened women) ≤ 1.2/1000 None specified Interval cancers within 25–36 months ≤ 1.4/1000 None specified Percentage rescreened within 36 months ≥ 90% 100% Percentage receiving screening result within 2 weeks ≥ 90% 100% Assessed within 3 weeks (% of total assessed) ≥ 90% 100% Percentage non-operative biopsies with result within 1 week ≥ 90% 100% Percentage referred to surgeon receiving surgical assessment within 1 week ≥ 90% 100% Percentage admitted for treatment within 2 months of referral ≥ 90% 100% DCIS, ductal carcinoma in situ. Adapted from Wilson & Liston (2011) and Department of Health (2013). aspects of image quality – that all units should specified for adverse effects of screening, such as attain, as well as achievable targets at which units radiation dose, and for rates of interval cancers, should aim. repeat examinations, and recalls for assessment. Table 5.1 pertains to a programme that In addition, maximum times to events in the targets women aged 50–70 years with a screening, diagnostic, and treatment processes maximum screening interval of 36 months in are specified; these are important for the patient’s high-incidence countries. In the example in experience and quality of life, although they do England, two-view mammography is used, and not necessarily reflect clinical or radiological the programme changed from film to digital quality. mammography during 2010–2014. Some of the criteria and standards are very Minimum standards are specified for specific to the programme. For example, the screening attendance and detection rates, in randomized trials of breast screening observe particular detection rates of small cancers, a higher rate of breast cancer detection at the which are expected to be high in an effective prevalent (first) screen than at incident (subse- screening programme. Maximum standards are quent) screens (see, for example, Tabár et al., 282 Breast cancer screening Table 5.2 Minimum quality standards for mammography in the USAa Criterion Standard Recall rate for assessment (% of screened women) < 10% Cancer detection rate, prevalent screen (per 1000 screened) 6–10 Cancer detection rate, incident screen (per 1000 screened) 2–4 Positive predictive value of recall for assessment 5–10% Positive predictive value of biopsy 25–40% Proportion of screen-detected cancers in situ or TNM stage 0–I > 50% Proportion of screen-detected node-positive cancers < 25% a Values are specified by the United States Agency for Health Care Policy and Research and endorsed by the American College of Radiology. TNM, tumour–node–metastasis staging system of malignant tumours (see Section 1, Table 1.9). Adapted from Bassett et al. (1994) and D’Orsi et al. (2013). 1992). However, the detection rate standards Indicators such as detection rates are typically are expected to be higher for incident screens part of the monitoring system of most screening because these values are based not on observa- programmes, but the actual target values will tions of a cohort recruited at the prevalent screen vary according to the screening regimen, the and followed up thereafter but on a programme target population, the underlying incidence in in which prevalent screens usually take place the programme’s location, and possibly aspects at about age 50 years and incident screens on of the health-care delivery systems and the medi- average at about age 60 years (when the under- colegal environment (Klabunde et al., 2001). lying risk of cancer is higher). Table 5.2 shows selected standards developed Another measure that is used in the United in the USA. These standards include acceptable Kingdom is the standardized detection ratio, ranges for positive predictive values (PPVs) of obtained by comparing the observed detection recall for assessment and for recommendation rates of invasive cancers by age with those of the for biopsy. They specify that the proportion of Swedish Two-County trial (Tabár et al., 1992), cases recalled for assessment that result in diag- on which the United Kingdom breast screening nosis of cancer should be 5–10%, and that the programme was modelled. At present, the proportion of biopsies that result in diagnosis standard is almost invariably exceeded (NHSBSP, of cancer should be 25–40%. These are powerful 2009), probably at least partly due to the fact that measures of the process since they reflect detection breast cancer incidence in the United Kingdom rates, recall rates, and biopsy rates. in the 21st century is higher than that in Sweden in the 1970s and 1980s. This example implies that (b) Screening sensitivity and interval cancers standards should be revised over time, although In a screening setting, the prevalence of it has also been observed that lower standards the disease in screened subjects, expressed as followed by remedial action have conferred a proportion, is usually very low; a very small substantial improvements in programme perfor- number of those screened at each screening mance (Blanks et al., 2002). Wallis et al. (2008) round are diagnosed with cancer, whereas thou- gave a demonstration of how careful surveillance sands of women are screened negative. Typically, of audit standards can lead to changes in prac- in European screening programmes, per 10 000 tice and improved performance at the local and women screened, about 9500 will have a normal national levels. initial result and about 500 will be recalled for further assessment, of whom about 70 will have 283 IARC HANDBOOKS OF CANCER PREVENTION – 15 breast cancer. After the screen, about 10–30 will potential to improve the programme’s ability to present with symptomatic interval cancer. detect
Recommended publications
  • Primary Screening for Breast Cancer with Conventional Mammography: Clinical Summary
    Primary Screening for Breast Cancer With Conventional Mammography: Clinical Summary Population Women aged 40 to 49 y Women aged 50 to 74 y Women aged ≥75 y The decision to start screening should be No recommendation. Recommendation Screen every 2 years. an individual one. Grade: I statement Grade: B Grade: C (insufficient evidence) These recommendations apply to asymptomatic women aged ≥40 y who do not have preexisting breast cancer or a previously diagnosed high-risk breast lesion and who are not at high risk for breast cancer because of a known underlying genetic mutation Risk Assessment (such as a BRCA1 or BRCA2 gene mutation or other familial breast cancer syndrome) or a history of chest radiation at a young age. Increasing age is the most important risk factor for most women. Conventional digital mammography has essentially replaced film mammography as the primary method for breast cancer screening Screening Tests in the United States. Conventional digital screening mammography has about the same diagnostic accuracy as film overall, although digital screening seems to have comparatively higher sensitivity but the same or lower specificity in women age <50 y. For women who are at average risk for breast cancer, most of the benefit of mammography results from biennial screening during Starting and ages 50 to 74 y. While screening mammography in women aged 40 to 49 y may reduce the risk for breast cancer death, the Stopping Ages number of deaths averted is smaller than that in older women and the number of false-positive results and unnecessary biopsies is larger. The balance of benefits and harms is likely to improve as women move from their early to late 40s.
    [Show full text]
  • Ductal Lavage in Women from BRCA1/2 Families: Is There a Future for Ductal Lavage in Women at Increased Genetic Risk of Breast Cancer?
    1243 Ductal Lavage in Women from BRCA1/2 Families: Is There a Future for Ductal Lavage in Women at Increased Genetic Risk of Breast Cancer? Jennifer T. Loud,1 Anne C.M. Thie´baut,4 Andrea D. Abati,2 Armando C. Filie,2 Kathryn Nichols,5 David Danforth,2 Ruthann Giusti,6 Sheila A. Prindiville,3 and Mark H. Greene1 1Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, 2Division of Clinical Sciences, and 3Office of the Director, National Cancer Institute, NIH, Bethesda, Maryland; 4INSERM, U657, Pasteur Institute, Paris, France; and 5Westat Corporation; 6Center for Biologics Evaluation and Research, Food and Drug Administration, Department of Health and Human Services, Rockville, Maryland Abstract Purpose: Ductal lavage has been used for risk stratifi- z10 cells. Postmenopausal women with intact ovaries cation and biomarker development and to identify compared with premenopausal women [odds ratio intermediate endpoints for risk-reducing intervention (OR), 4.8; P = 0.03] and women without a prior breast trials. Little is known about patient characteristics cancer history (OR, 5.2; P = 0.04) had an increased associated with obtaining nipple aspirate fluid (NAF) likelihood of yielding NAF. Having breast-fed (OR, and adequate cell counts (z10 cells) in ductal lavage 3.4; P = 0.001), the presence of NAF before ductal specimens from BRCA mutation carriers. lavage (OR, 3.2; P = 0.003), and being premenopausal Methods: We evaluated patient characteristics associat- (OR, 3.0; P = 0.003) increased the likelihood of ductal ed with obtaining NAF and adequate cell counts in lavage cell count adequacy. In known BRCA1/2 ductal lavage specimens from the largest cohort of mutation carriers, only breast-feeding (OR, 2.5; P = women from BRCA families yet studied (BRCA1/2 = 0.01) and the presence of NAF (OR, 3.0; P = 0.01) were 146, mutation-negative = 23, untested = 2).
    [Show full text]
  • Early Detection and Screening for Breast Cancer
    Seminars in Oncology Nursing, Vol 33, No 2 (May), 2017: pp 141-155 141 EARLY DETECTION AND SCREENING FOR BREAST CANCER CATHY COLEMAN OBJECTIVE: To review the history, current status, and future trends related to breast cancer screening. DATA SOURCES: Peer-reviewed articles, web sites, and textbooks. CONCLUSION: Breast cancer remains a complex, heterogeneous disease. Serial screening with mammography is the most effective method to detect early stage disease and decrease mortality. Although politics and economics may inhibit organized mammography screening programs in many countries, the judi- cious use of proficient clinical and self-breast examination can also identify small tumors leading to reduced morbidity. IMPLICATIONS FOR NURSING PRACTICE: Oncology nurses have exciting oppor- tunities to lead, facilitate, and advocate for delivery of high-quality screening services targeting individuals and communities. A practical approach is needed to translate the complexities and controversies surrounding breast cancer screen- ing into improved care outcomes. KEY WORDS: breast cancer, screening, early stage, quality, breast centers, advocacy. he future is hopeful for the public, pro- fessionals, and interdisciplinary teams as multifaceted progress continues to reveal new insights in carcinogenesis, ge- Cathy Coleman, DNP, MSN, PHN, OCN®, CPHQ, CNL: T nomics, tumor biology, translational research, and Assistant Professor, University of San Francisco School quality improvement from prevention to pallia- of Nursing and Health Professions, San Francisco, CA. tion and survivorship for cancer care.1-8 Oncology Address correspondence to Cathy Coleman, DNP, nurses are on the front line of care delivery across MSN, PHN, OCN®, CPHQ, CNL, University of San settings; they also assert a strong leadership voice Francisco School of Nursing and Health Professions, 2130 Fulton Street, San Francisco, CA 94117.
    [Show full text]
  • State of Science Breast Cancer Fact Sheet
    Patient Version Breast Cancer Fact Sheet About Breast Cancer Breast cancer can start in any area of the breast. In the US, breast cancer is the most common cancer (after skin cancer) and the second-leading cause of cancer death (after lung cancer) in women. Risk Factors Risk factors for breast cancer that you cannot change Lifestyle-related risk factors for breast cancer include: • Drinking alcohol Being born female • Being overweight or obese, especially after menopause This is the main risk factor for breast cancer. But men can get breast cancer, too. • Not being physically active Getting older • Getting hormone therapy after menopause with As a person gets older, their risk of breast cancer estrogen and progesterone therapy goes up. Most breast cancers are found in women • Starting menstruation early or having late menopause age 55 or older. • Never having children or having first live birth after Personal or family history age 30 A woman who has had breast cancer in the past or has a • Using certain types of birth control close blood relative who has had breast cancer (mother, • Having a history of non-cancerous breast conditions father, sister, brother, daughter) has a higher risk of getting it. Having more than one close blood relative increases the risk even more. It’s important to know that Prevention most women with breast cancer don’t have a close blood There is no sure way to prevent breast cancer, and relative with the disease. some risk factors can’t be changed, such as being born female, age, race, and personal or family history of the Inheriting gene changes disease.
    [Show full text]
  • Stochastic Models for Improving Screening and Surveillance Decisions for Prostate Cancer Care
    Stochastic Models for Improving Screening and Surveillance Decisions for Prostate Cancer Care by Christine Barnett A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Industrial and Operations Engineering) in The University of Michigan 2017 Doctoral Committee: Professor Brian T. Denton, Chair Associate Professor Mariel S. Lavieri Professor Lawrence M. Seiford Assistant Professor Scott A. Tomlins Christine L. Barnett clbarnet@umich.edu ORCID iD: 0000-0002-1465-7623 c Christine L. Barnett 2017 DEDICATION For Jon, Amy, and Kate. ii ACKNOWLEDGEMENTS First, I would like to thank my advisor, Dr. Brian Denton, for his guidance and support over the past five years. I am grateful to have had him as a mentor through this experience, and feel prepared for the next stage in my career thanks to his encouragement and guidance. This work was supported in part by the National Sci- ence Foundation through Grant Number CMMI 0844511 and by the National Science Foundation Graduate Research Fellowship under Grant Number DGE 1256260. I would like to thank my committee members Dr. Mariel Lavieri, Dr. Lawrence Seiford, and Dr. Scott Tomlins for serving on my committee and providing me with career advice and helpful feedback on my research. In addition, I would like to thank our collaborators from Michigan Medicine, Dr. Gregory Auffenberg, Dr. Matthew Davenport, Dr. Jeffrey Montgomery, Dr. James Montie, Dr. Todd Morgan, Dr. Scott Tomlins, and Dr. John Wei for their invaluable clinical perspective and for teaching me about the intricacies of prostate cancer screening and treatment decisions. Finally, I would like to thank my friends and family for their support throughout graduate school.
    [Show full text]
  • Breast Care / Breast Cancer
    BREAST CARE / BREAST CANCER Overview The Kaiser Permanente Breast Care Management Algorithm provided on this site was developed by the Inter-Regional Breast Cancer leaders group (IRBC). This multidisciplinary group includes physicians from Primary Care, Surgery, Oncology, Obstetrics and Gynecology, Radiology, Mammography, Genetics and Women’s Services and representatives from various regional Breast Cancer Task force groups, Clinical Nursing, Quality Resource & Risk Management, Public Relations & Issues Management, Prevention Services, and the Permanente Federation. The algorithm was developed to: • Improve the quality of care for our members with breast complaints, • Improve the timeliness of the identification of breast abnormalities and diagnosis of breast cancer, • Improve the satisfaction of members with breast complaints, and • Respond to the increase in malpractice allegations of failure to diagnose breast cancer. In 2002, the IRBC group held periodic conference calls to develop information to assist primary care clinicians in improving the quality of care for patients with breast complaints. A multidisciplinary consensus-based method was used to develop the content of the algorithm. The group also identified additional information and resources available internally and externally which would support implementation.The Breast Care Leaders in each Region have been encouraged to review and modify the algorithm to reflect local operations. Therefore, prior to use, PCPs are advised to contact a Regional member of the Inter-Regional Breast Care leaders group about revisions for your Region This site is for use within Kaiser Permanente only. What is Available on this Site? The IRBC group and the project management staff from the Permanente Federation worked together to define the project scope and develop the following products and information: I.
    [Show full text]
  • What You Should Know About Breast Cancer Screening
    Cancer AnswerLineTM WHAT YOU SHOULD KNOW ABOUT BREAST CANCER SCREENING Women should speak to their health care provider about their risk of breast cancer and whether a screening test is right for them, as well as to review the risks and benefits of screening. The purpose of screening is to find disease early; THE AMERICAN CANCER SOCIETY’S ideally before symptoms appear. Almost all diseases, RECOMMENDATIONS: including cancer, are easier to treat in an earlier • Women between 40 and 44 have the option to stage as opposed to an advanced stage. start screening with a mammogram every year. Women 45 to 54 should get mammograms every While experts may have different opinions regarding • year. when to begin mammography screening and at what frequency, all major U.S. organizations, • Women 55 and older can switch to a mammogram including the American Cancer Society, the every other year, or they can choose to continue National Comprehensive Cancer Network and the yearly mammograms. Screening should continue U.S. Preventive Services Task Force continue to as long as a woman is in good health and is recommend regular screening mammography to expected to live 10 more years or longer. reduce breast cancer mortality. Breast cancer • All women should understand what to expect mortality rates have continued to decrease in the when getting a mammogram for breast cancer United States due to advances in screening and screening—what the test can and cannot do. treatment over the last 20 years. These recommendations apply to asymptomatic Breast cancer screening is broken down into women aged 40 years or older who do not have different classifications based the patient’s age, level preexisting breast cancer or a previously diagnosed of risk (how likely they are to get breast cancer), and high-risk breast lesion and who are not at high risk strength of the recommendation.
    [Show full text]
  • Breast Self-Examination Practices in Women Who
    Breast self-examination practices in women who have had a mastectomy by Carole H Crowell A thesis submitted in partial fulfillment of the requirement for the degree of Master of Nursing Montana State University © Copyright by Carole H Crowell (1990) Abstract: Research findings indicate that breast cancer mortality has not decreased significantly in the past decade. While research continues on the development of more effective therapies, techniques for early detection are presently receiving greater attention. The use of breast self-examination (BSE) has been emphasized in the media and professional literature but little emphasis has been placed on BSE for women who have had a mastectomy. The purposes of this study were to determine if women who have had breast surgery do breast self-examination and to describe barriers that block this behavior. An assumption was made that women who have had surgery for breast cancer do not examine their remaining breast tissue and scar site. A qualitative study was conducted using a grounded theory approach to explore and describe behavior of women who have had a mastectomy. Analytic strategies used for data analysis were the constant comparative method, theoretical sampling, open coding, memo writing, and recoding. A convenience sample of twelve informants was selected from a mastectomy support group located in a rural community in Montana. BSE was viewed as a health-promoting behavior and was found to relate to certain variables of Penders (1987) Health Promotion Model. Findings of this study indicate a majority of women perform BSE after their mastectomy but most do not examine their scar site.
    [Show full text]
  • Breast Cancer Screening in Women at Higher-Than-Average Risk: Recommendations from the ACR
    ORIGINAL ARTICLE CLINICAL PRACTICE MANAGEMENT Breast Cancer Screening in Women at Higher-Than-Average Risk: Recommendations From the ACR Debra L. Monticciolo, MDa, Mary S. Newell, MDb, Linda Moy, MDc, Bethany Niell, MD, PhDd, Barbara Monsees, MDe, Edward A. Sickles, MD f Credits awarded for this enduring activity are designated “SA-CME” by the American Board of Radiology (ABR) and qualify toward fulfilling requirements for Maintenance of Certification (MOC) Part II: Lifelong Learning and Self-assessment. To access the SA-CME activity visit https://3s.acr.org/Presenters/CaseScript/CaseView?CDId¼5qIPiGþnl6k%3d. Abstract Early detection decreases breast cancer mortality. The ACR recommends annual mammographic screening beginning at age 40 for women of average risk. Higher-risk women should start mammographic screening earlier and may benefit from supplemental screening modalities. For women with genetics-based increased risk (and their untested first-degree relatives), with a calculated lifetime risk of 20% or more or a history of chest or mantle radiation therapy at a young age, supplemental screening with contrast-enhanced breast MRI is recommended. Breast MRI is also recommended for women with personal histories of breast cancer and dense tissue, or those diagnosed by age 50. Others with histories of breast cancer and those with atypia at biopsy should consider additional surveillance with MRI, especially if other risk factors are present. Ultrasound can be considered for those who qualify for but cannot undergo MRI. All women, especially black women and those of Ashkenazi Jewish descent, should be evaluated for breast cancer risk no later than age 30, so that those at higher risk can be identified and can benefit from supplemental screening.
    [Show full text]
  • Official Proceedings
    Scientific Session Awards Abstracts presented at the Society’s annual meeting will be considered for the following awards: • The George Peters Award recognizes the best presentation by a breast fellow. In addition to a plaque, the winner receives $1,000. The winner is selected by the Society’s Publications Committee. The award was established in 2004 by the Society to honor Dr. George N. Peters, who was instrumental in bringing together the Susan G. Komen Breast Cancer Foundation, The American Society of Breast Surgeons, the American Society of Breast Disease, and the Society of Surgical Oncology to develop educational objectives for breast fellowships. The educational objectives were first used to award Komen Interdisciplinary Breast Fellowships. Subsequently the curriculum was used for the breast fellowship credentialing process that has led to the development of a nationwide matching program for breast fellowships. • The Scientific Presentation Award recognizes an outstanding presentation by a resident, fellow, or trainee. The winner of this award is also determined by the Publications Committee. In addition to a plaque, the winner receives $500. • All presenters are eligible for the Scientific Impact Award. The recipient of the award, selected by audience vote, is honored with a plaque. All awards are supported by The American Society of Breast Surgeons Foundation. The American Society of Breast Surgeons 2 2017 Official Proceedings Publications Committee Chair Judy C. Boughey, MD Members Charles Balch, MD Sarah Blair, MD Katherina Zabicki Calvillo, MD Suzanne Brooks Coopey, MD Emilia Diego, MD Jill Dietz, MD Mahmoud El-Tamer, MD Mehra Golshan, MD E. Shelley Hwang, MD Susan Kesmodel, MD Brigid Killelea, MD Michael Koretz, MD Henry Kuerer, MD, PhD Swati A.
    [Show full text]
  • Collaborative Modeling of U.S. Breast Cancer Screening Strategies
    Technical Report Collaborative Modeling of U.S. Breast Cancer Screening Strategies Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither Road Rockville, MD 20850 Prepared by: Writing Committee of the Breast Cancer Working Group Cancer Intervention and Surveillance Modeling Network (CISNET) and the Breast Cancer Surveillance Consortium (BCSC) Writing Committee Members: Jeanne Mandelblatt Kathy Cronin Harry de Koning Diana L. Miglioretti Clyde Schechter Natasha Stout AHRQ Publication No. 14-05201-EF-4 December 2015 The modeling analysis included in this report was done by six independent teams from the Dana- Farber Cancer Institute (PI: Lee); Erasmus University (PI: de Koning); Georgetown University Medical Center, Lombardi Comprehensive Cancer Center/Albert Einstein College of Medicine (PI: Mandelblatt/Schechter); University of Wisconsin/Harvard Medical School, Harvard Pilgrim Health Care (PI: Trentham-Dietz/Stout); M.D. Anderson Comprehensive Cancer Center (PI: Berry); and Stanford University (PI: Plevritis). This work was supported by the National Institutes of Health under National Cancer Institute Grant U01 CA152958 and the National Cancer Institute-funded Breast Cancer Surveillance Consortium (BCSC) Grant P01 CA154292, contract HSN261201100031C, and Grant U54CA163303. The collection of BCSC cancer and vital status data used in this study was supported in part by several state public health departments and cancer registries throughout the United States. For a full description of these sources, go to: http://breastscreening.cancer.gov/work/acknowledgement.html. Model results and the contents of this report are the sole responsibility of the investigators. Authors and Affiliations Jeanne S. Mandelblatt, Aimee M. Near, Amanda Hoeffken, and Yaojen Chang: Department of Oncology, Georgetown University Medical Center and Cancer Prevention and Control Program, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC Natasha K.
    [Show full text]
  • Mammary Ductoscopy, Aspiration and Lavage
    Cigna Medical Coverage Policy Effective Date ............................ 2/15/2014 Subject Mammary Ductoscopy, Next Review Date ...................... 2/15/2015 Coverage Policy Number ................. 0057 Aspiration and Lavage Table of Contents Related Coverage Policies Coverage Policy .................................................. 1 Emerging Breast Biopsy/Localization General Background ........................................... 1 Procedures Coding/Billing Information ................................. 10 Electrical Impedance Scanning (EIS) and References ........................................................ 10 Optical Imaging of the Breast Genetic Testing for Susceptibility to Breast and Ovarian Cancer (e.g., BRCA1 & BRCA2) Magnetic Resonance Imaging (MRI) of the Breast Mammography Prophylactic Mastectomy INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna companies. Coverage Policies are intended to provide guidance in interpreting certain standard Cigna benefit plans. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer’s benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation.
    [Show full text]